An observational study in Axial Spondyloarthritis, Ankylosing Spondylitis and Spondylarthritis, sponsored by Ankara Etlik City Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Ankara Etlik City Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Spondylitis, Ankylosing with a site in Turkey — 19 open to participants now, 21 under way, none of them phase 3. Spondylitis, Ankylosing · Turkey.
Among the 84 studies in Spondylitis, Ankylosing with a site in Turkey, this one is the 29th largest by planned enrollment of the 35 observational ones that give a count, is one of 9 that started in 2026, is one of 35 observational ones, reaches primary completion later than 17 of the 20 other live ones, and was the 81st registered.
535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.
Browse Spondylitis, Ankylosing studies →19 of the 84 studies in Spondylitis, Ankylosing with a site in Turkey are open now. Recruiting first, the newest first:
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–65
Marmara University · Sites in Turkey
Ages 18–65
Merve Şahin · Sites in Turkey
Ages 18–65 · Healthy volunteers
Konya Beyhekim Training and Research Hospital · Sites in Turkey
Ages 18+
Kirsehir Ahi Evran Universitesi · Sites in Turkey
Ages 18–85
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 53 is below the median of 201 across 216 observational studies indexed under Spondylitis, Ankylosing.
Median enrollment 60 across the 49 interventional studies, 100 across the 35 observational. Of the 54 that completed or were terminated, 11 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 84 have an industry lead sponsor. The 10 most frequent:
Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 77 are open to participants now.
Ankara Etlik City Hospital has 1 study filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
9 of the studies in Spondylitis, Ankylosing with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07627542Merve ŞahinAn Investigation of the Effect of Smartphone Usage Levels on Cervical Posture, Tongue Pressure, Balance, and Neck Disability in Individuals With Rheumatoid Arthritis and Ankylosing Spondylitis | 2026-11 |
| NCT07170384Sinem Kübra BekeMediterranean Diet and Disease Activity in Axial Spondyloarthritis Receiving Biologic Therapy | 2027-01-01 |
| NCT07633730Marmara UniversityEfficacy of the Erector Spinae Plane Block for Persistent Back Pain in Patients With Ankylosing Spondylitis | 2027-05-02 |
| NCT05096767Bozyaka Training and Research HospitalNeuropathic Spinal Pain Descriptors in Ankylosing Spondylitis | 2027-05-05 |
| NCT07776652Istanbul University - CerrahpasaPostural Biofeedback and Exercise in Axial Spondyloarthritis | 2027-05-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 84 studies in Spondylitis, Ankylosing with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Radiographic axial spondyloarthritis (r-axSpA) causes progressive structural damage of the spine, conventionally quantified on lateral cervical and lumbar radiographs using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Repeated radiography entails cumulative radiation exposure, substantial inter-reader variability and low sensitivity in early disease. DIERS Formetric 4D (four-dimensional) surface topography (DIERS International GmbH, Schlangenbad, Germany) provides radiation-free three-dimensional modelling of the spine and pelvis. The association between sagittal balance and structural damage has been demonstrated with a radiation-based biplanar low-dose radiography system (EOS imaging, Paris, France), but whether a radiation-free topographic method reflects the same association has not been investigated.
This single-centre, cross-sectional observational study will enrol 53 adults with r-axSpA fulfilling the Assessment of SpondyloArthritis international Society (ASAS) criteria with radiographic sacroiliitis according to the modified New York criteria. At a single study visit, static DIERS Formetric 4D measurements, chest expansion, the Bath Ankylosing Spondylitis Metrology Index (BASMI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) are obtained. mSASSS is scored by a single reader, blinded to clinical and topographic data, on existing lateral cervical and lumbar radiographs obtained within the preceding 12 months; no additional radiographs are performed for the study. The primary analysis is the correlation between total mSASSS and the DIERS flèche cervicale (cervical sagittal anterior displacement).
Design: single-centre, cross-sectional, non-interventional correlation study in a single patient group; no control group. All participant data are collected in one assessment session lasting approximately 45 to 60 minutes.
Measurements: (a) demographic and anthropometric data; (b) disease duration, age at symptom onset, comorbidities, extra-articular involvement (uveitis, inflammatory bowel disease, psoriasis), human leukocyte antigen B27 (HLA-B27) status, current medication category; (c) radiographic sacroiliitis grade according to the modified New York criteria and the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS; range 0 to 72), scored by a single reader blinded to clinical and topographic data; (d) chest expansion; (e) the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), the latter using routine C-reactive protein values with no additional blood sampling; (f) Bath Ankylosing Spondylitis Metrology Index (BASMI) total score and its five components; (g) DIERS Formetric 4D (four-dimensional) static parameters: flèche cervicale (cervical sagittal anterior displacement, mm), sagittal imbalance (mm and degrees), coronal imbalance (mm), pelvic obliquity (mm), pelvic torsion (degrees), cervical and lumbar depth distance (mm), kyphotic angle (degrees) and lordotic angle (degrees).
Statistical analysis: distribution is assessed with the Shapiro-Wilk test. The primary analysis is a Pearson or Spearman correlation between total mSASSS and flèche cervicale, reported with effect size and 95% confidence interval, followed by multiple linear regression adjusted for age and disease duration. Secondary analyses comprise correlations of DIERS parameters with clinical indices and an exploratory receiver operating characteristic analysis of the ability of DIERS sagittal parameters to predict mSASSS thresholds. The Benjamini-Hochberg procedure is applied to correct for multiple comparisons. Significance is set at p\<0.05. Analyses are performed with IBM SPSS Statistics (Statistical Package for the Social Sciences) version 23 or later.
Sample size: calculated with G*Power 3.1.9 for a bivariate normal correlation model, two-tailed, correlation under the null hypothesis (rho H0) = 0, expected effect size r = 0.40, alpha = 0.05 and power = 0.85, giving a required sample of 53 participants (actual power 0.857). The effect size was set conservatively at r = 0.40 rather than the r = 0.61 reported by Wanders et al. (2005) for occiput-to-wall distance versus mSASSS, because DIERS parameters are not identical to clinical mobility measures.
Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.
535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.
This study's planned enrollment of 53 is below the median of 201 across 216 observational studies indexed under Spondylitis, Ankylosing.
Browse Spondylitis, Ankylosing studies →Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 77 are open to participants now.
Compared within Spondylitis, Ankylosing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Axial Spondyloarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The criteria were revised on the registry on Nov 12, 2026. See what changed
Consecutive patients with radiographic axial spondyloarthritis attending the spondyloarthritis outpatient clinic of the Department of Physical Medicine and Rehabilitation, Ankara Etlik City Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 18 to 65 years with radiographic axial spondyloarthritis fulfilling the Assessment of SpondyloArthritis international Society (ASAS) classification criteria with radiographic sacroiliitis according to the modified New York criteria, attending the spondyloarthritis outpatient clinic. All participants undergo a single assessment session including static DIERS Formetric 4D surface topography, chest expansion and clinical indices: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI) and Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP). The modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) is scored on existing lateral cervical and lumbar radiographs obtained within the preceding 12 months; no additional radiographs are taken.
Diagnostic Test: DIERS Formetric 4D surface topography
Radiation-free three-dimensional assessment of spinal and pelvic surface topography performed once in standing position. No radiation, no contact, no intervention on treatment.
Correlation between total mSASSS and DIERS fleche cervicale
Total modified Stoke Ankylosing Spondylitis Spine Score (mSASSS; range 0 to 72, higher scores indicate greater structural damage), correlated with flèche cervicale (cervical sagittal anterior displacement, mm) measured by DIERS Formetric 4D surface topography. Reported as a correlation coefficient with magnitude, direction and 95% confidence interval.
Time frame: Single assessment session (Day 1); mSASSS scored on radiographs obtained within the 12 months preceding the assessment
Correlation between total mSASSS and other DIERS Formetric static parameters
Total modified Stoke Ankylosing Spondylitis Spine Score (mSASSS; range 0 to 72, higher scores indicate greater structural damage) correlated with the remaining DIERS Formetric 4D static parameters: sagittal imbalance (mm and degrees), coronal imbalance (mm), pelvic obliquity (mm), pelvic torsion (degrees), cervical depth distance (mm), lumbar depth distance (mm), kyphotic angle (degrees) and lordotic angle (degrees). Reported as correlation coefficients with 95% confidence intervals.
Time frame: Single assessment session (Day 1); mSASSS scored on radiographs obtained within the 12 months preceding the assessment
Correlation between DIERS sagittal parameters and BASDAI
Bath Ankylosing Spondylitis Disease Activity Index (range 0 to 10, higher scores indicate greater disease activity) correlated with DIERS Formetric 4D static parameters: flèche cervicale (mm), sagittal imbalance (mm and degrees), coronal imbalance (mm), pelvic obliquity (mm), pelvic torsion (degrees), cervical and lumbar depth distance (mm), kyphotic angle (degrees) and lordotic angle (degrees).
Time frame: Single assessment session (Day 1)
Correlation between DIERS sagittal parameters and BASFI
Bath Ankylosing Spondylitis Functional Index (range 0 to 10, higher scores indicate worse physical function) correlated with DIERS Formetric 4D static parameters: flèche cervicale (mm), sagittal imbalance (mm and degrees), coronal imbalance (mm), pelvic obliquity (mm), pelvic torsion (degrees), cervical and lumbar depth distance (mm), kyphotic angle (degrees) and lordotic angle (degrees).
Time frame: Single assessment session (Day 1)
Correlation between DIERS sagittal parameters and BASMI
Bath Ankylosing Spondylitis Metrology Index (range 0 to 10, higher scores indicate worse spinal mobility) correlated with DIERS Formetric 4D static parameters: fleche cervicale (mm), sagittal imbalance (mm and degrees), coronal imbalance (mm), pelvic obliquity (mm), pelvic torsion (degrees), cervical and lumbar depth distance (mm), kyphotic angle (degrees) and lordotic angle (degrees).
Time frame: Single assessment session (Day 1)
Correlation between DIERS sagittal parameters and ASDAS-CRP
Ankylosing Spondylitis Disease Activity Score with C-reactive protein (higher scores indicate greater disease activity) correlated with DIERS Formetric 4D static parameters: fleche cervicale (mm), sagittal imbalance (mm and degrees), coronal imbalance (mm), pelvic obliquity (mm), pelvic torsion (degrees), cervical and lumbar depth distance (mm), kyphotic angle (degrees) and lordotic angle (degrees).
Time frame: Single assessment session (Day 1)
Correlation between DIERS sagittal parameters and chest expansion
Chest expansion measured in centimetres correlated with DIERS Formetric 4D static parameters: flèche cervicale (mm), sagittal imbalance (mm and degrees), coronal imbalance (mm), pelvic obliquity (mm), pelvic torsion (degrees), cervical and lumbar depth distance (mm), kyphotic angle (degrees) and lordotic angle (degrees).
Time frame: Single assessment session (Day 1)
Discriminative performance of DIERS sagittal parameters for mSASSS thresholds
Exploratory receiver operating characteristic analysis of DIERS Formetric 4D sagittal parameters for discriminating total modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) thresholds. Reported as area under the curve with 95% confidence interval, sensitivity and specificity.
Time frame: Single assessment session (Day 1); mSASSS scored on radiographs obtained within the 12 months preceding the assessment
Plan to share: No — Individual participant data will not be shared. According to the study protocol, research data are accessible only to the investigators. Aggregate results will be published.
Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Jun 2027, on Nov 12, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.